Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung ...

With the daily environmental pollution taking a massive toll on our lungs as evidenced by the poor air quality index (AQI) of ...

Specialists in Mumbai and Delhi whom TOI spoke to, said that two anti-fibrotic medications aimed at reducing the scarred lung tissues are the mainstay of IPF treatment. "Most of our patients don't ...

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

In a report released yesterday, Faisal Khurshid from Leerink Partners maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report), ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

There are also several side effects with approved IPF drugs, including commonly reported symptoms such as diarrhoea, nausea, and stomach pain, which affect around two thirds of patients taking Ofev.